human immunodeficiency virus type 1 (HIV-1) research hub

An Operationally Seamless Phase 2/3 Randomized, Open-label, Active-Controlled Study Evaluating the Safety and Efficacy of an Injectable Regimen of GS-3242 in Combination with Lenacapavir Versus Biktarvy (Bictegravir/Emtricitabine/Tenofovir Alafenamide) in Treatment-Naive People With HIV-1

This clinical trial looks at a new long-acting injection for adults with HIV-1 who have not started treatment before. It compares an injectable combination of two medicines, GS-3242 and lenacapavir, against a standard daily tablet called Biktarvy. The goal is to see if injections work just as well as daily pills.